Compare USIO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USIO | SPRO |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 67.0M |
| IPO Year | 1999 | 2017 |
| Metric | USIO | SPRO |
|---|---|---|
| Price | $2.82 | $1.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $5.92 | $5.00 |
| AVG Volume (30 Days) | 197.7K | ★ 839.8K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ 0.01 | N/A |
| Revenue | $28,200,535.00 | ★ $66,802,000.00 |
| Revenue This Year | $14.57 | N/A |
| Revenue Next Year | $11.98 | N/A |
| P/E Ratio | $285.50 | ★ N/A |
| Revenue Growth | 12.69 | ★ 39.24 |
| 52 Week Low | $1.03 | $1.08 |
| 52 Week High | $3.06 | $3.08 |
| Indicator | USIO | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 41.51 |
| Support Level | $2.15 | $1.10 |
| Resistance Level | $3.03 | $1.28 |
| Average True Range (ATR) | 0.17 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 67.74 | 2.50 |
Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.